Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) is now available.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is undergoing a proposed conditional privatization by Sunshine Lake Pharma Co., Ltd. through a merger by absorption. This process involves the withdrawal of the company’s listing and the dispatch of a composite document to shareholders. The composite document, which includes details about the merger, listing, and recommendations from the Independent Board Committee and the Independent Financial Adviser, will be sent to shareholders on June 30, 2025. This move is significant as it marks a strategic shift in the company’s operations, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
Average Trading Volume: 9,690,048
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.11B
For an in-depth examination of 1558 stock, go to TipRanks’ Overview page.